Vilon (Lys-Glu) is a short synthetic bioregulatory dipeptide extensively evaluated in preclinical models for its role in modulating chromatin structure, cellular proliferation, and epithelial tissue homeostasis. Researchers seeking to buy Vilon for gastrointestinal support studies can access high-purity, laboratory-grade compounds backed by lot-specific analytical verification through PX1 Research.
Vilon (Lys-Glu) is a short synthetic bioregulatory dipeptide extensively evaluated in preclinical models for its role in modulating chromatin structure, cellular proliferation, and epithelial tissue homeostasis. Researchers seeking to buy Vilon for gastrointestinal support studies can access high-purity, laboratory-grade compounds backed by lot-specific analytical verification through PX1 Research.
Vilon is a synthetic dipeptide composed of L-lysine and L-glutamic acid (Lys-Glu). Originally derived from short-chain peptide research investigating thymic bioregulators, Vilon has become a primary candidate in studies targeting cellular aging, immune-epithelial crosstalk, and mucosal lining stability. In preclinical settings, researchers evaluate Vilon to observe how low-molecular-weight peptides cross cell membranes and interact directly with nuclear material to regulate gene transcription.
When investigators look to buy Vilon gastrointestinal support formulations for laboratory experimentation, the primary objective is typically to measure enterocyte turnover, tight-junction protein expression, and localized inflammatory responses. Because of its minimal sequence length, Vilon exhibits high stability in vitro compared to larger protein constructs, making it an advantageous compound for assaying fundamental bioregulatory pathways in gut tissue culture models.
The primary mechanism of action attributed to Vilon in published literature involves direct interaction with the genomic structure of targeted cells. In vitro assays demonstrate that short dipeptides like Lys-Glu penetrate the nuclear envelope and bind to specific histone proteins and DNA promoter regions. This binding alters chromatin conformation from heterochromatin (condensed, inactive) to euchromatin (relaxed, active), effectively modulating transcriptional activity without altering the core genetic code.
In intestinal epithelial cell lines, this epigenetic derepression leads to altered expression of proteins responsible for cellular repair, antioxidant defense, and structural integrity. Preclinical rodent models suggest that Vilon administration induces activation of ribosomal DNA transcription, accelerating protein synthesis necessary for tissue maintenance following oxidative or inflammatory stress. Researchers exploring these pathways can review broader mechanisms within our bioregulatory peptides mechanism guide.
Gastrointestinal integrity relies heavily on the continuous regeneration of the mucosal barrier and rapid turnover of enterocytes lining the lumen. In animal models subjected to mucosal damage or radiation-induced enteropathy, treatment with Vilon demonstrated a statistically significant reduction in epithelial apoptosis and an increased mitotic index within crypt cells. These findings suggest that Vilon supports intestinal barrier restoration by promoting controlled cellular proliferation.
Furthermore, preclinical studies examining age-related gastrointestinal atrophy indicate that Lys-Glu supplementation helps preserve villus height and crypt depth. By maintaining structural architecture, Vilon aids in sustaining normal nutrient transport markers and preventing excessive hyper-permeability in experimental models of gut barrier breakdown.
When designing protocols for mucosal integrity or inflammatory gut models, researchers often compare Vilon against established compounds in the gastrointestinal research catalog. While Vilon functions predominantly through direct gene transcription and chromatin uncoiling, other agents target distinct cell-signaling cascades.
For instance, BPC-157 acts primarily through VEGFR2 upregulation, focal adhesion kinase signaling, and rapid angiogenesis acceleration, making it ideal for acute wound healing models. In contrast, Larazotide functions as a synthetic peptide antagonist of zonulin receptors, specifically targeting tight junction assembly to prevent paracellular permeability. Meanwhile, KPV peptide exerts potent anti-inflammatory effects via nuclear factor-kappa B (NF-κB) inhibition in intestinal epithelial cells, and Thymogen (Glu-Trp) shares Vilon's bioregulatory framework with a stronger emphasis on systemic T-cell maturation. Exploring our comprehensive gastrointestinal peptides overview provides additional comparative context for multi-target trial designs.
The validity of preclinical gut research depends entirely on the chemical purity and structural identity of the synthesized peptide. Minor impurities, such as unreacted amino acid precursors or truncated peptide fragments, can skew binding assays, alter cellular toxicity profiles, and yield inconsistent assay results. Therefore, acquiring Vilon requires rigorous analytical verification.
At PX1 Research, every batch of Vilon undergoes strict quality control testing at our ISO 17025 accredited analytical facility. Purity is established using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC), ensuring a baseline purity of ≥98%. Structural verification is performed via Electrospray Ionization Mass Spectrometry (ESI-MS) to confirm exact molecular weight. Every shipment includes a lot-specific Certificate of Analysis (COA) detailing these metrics for complete regulatory and experimental compliance.
In gastrointestinal research involving primary tissue cultures, organoids, or delicate cell lines (such as Caco-2 or HT29), bacterial endotoxins (lipopolysaccharides) present a severe confounding variable. Endotoxin contamination triggers immune activation via Toll-like receptor 4 (TLR4), masking the true physiological effects of the peptide under investigation.
PX1 Research enforces stringent endotoxin control measures across all synthetic batches. Utilizing the Chromogenic Limulus Amebocyte Lysate (LAL) assay, our peptides are certified to contain endotoxin levels below 0.01 EU/mg. All compounds are synthesized in GMP-compliant, US-based laboratories, guaranteeing that your in vitro models remain free from exogenous pyrogens or bacterial debris. Learn more about our manufacturing standards in the PX1 research library.
Vilon is supplied as a lyophilized (freeze-dried) powder to maximize chemical stability during transport and storage. To preserve peptide integrity prior to assay deployment, researchers must adhere to standard laboratory handling guidelines:
1. **Reconstitution:** Allow the vial to equilibrate to room temperature before reconstitution to prevent condensation inside the container. Reconstitute using sterile, nuclease-free water or phosphate-buffered saline (PBS, pH 7.4) under a laminar flow hood. 2. **Solubility:** Lys-Glu is highly hydrophilic and readily dissolves in aqueous media without the need for organic co-solvents like DMSO. 3. **Aliquoting and Storage:** Following initial reconstitution, aliquot the solution into single-use microcentrifuge tubes to prevent degradation from repeated freeze-thaw cycles. Store long-term stock solutions at -20°C or -80°C, and store unopened lyophilized vials at -20°C dry.
Researchers seeking to buy Vilon gastrointestinal support peptides demand supply chain transparency, rapid logistics, and uncompromising batch consistency. PX1 Research operates state-of-the-art facilities located in California and Arizona, providing immediate processing and same-day shipping (Monday through Friday) for all domestic research orders.
Whether executing small-scale bench assays or establishing high-throughput screening initiatives, institutions can access fully verified research compounds directly through our catalog of peptides. For large-scale research projects or institutional procurement, explore customized fulfillment through our wholesale lab account portal.
What is the primary sequence of Vilon?
Vilon is a synthetic dipeptide composed of L-lysine and L-glutamic acid, commonly referred to as Lys-Glu or KED.
How is Vilon studied in gastrointestinal research models?
Preclinical literature evaluates Vilon for its ability to interact with enterocyte chromatin, modulate intestinal epithelial cell proliferation, preserve crypt-villus architecture, and regulate local immune-inflammatory responses.
How does PX1 Research verify the purity of Vilon?
Every lot of Vilon undergoes independent analytical testing utilizing RP-HPLC for purity (>98%) and Mass Spectrometry (ESI-MS) for molecular weight confirmation. A lot-specific Certificate of Analysis (COA) is accessible with every order.
What are the endotoxin limits for PX1 Research peptides?
PX1 Research peptides are batch-tested using chromogenic LAL assays to ensure endotoxin levels remain strictly below 0.01 EU/mg, minimizing cellular toxicity in sensitive in vitro and tissue culture models.
How should lyophilized Vilon be stored upon arrival?
Unopened, lyophilized Vilon should be stored at -20°C in a dry environment. Once reconstituted in sterile buffer or water, solutions should be aliquoted and stored at -20°C or -80°C to avoid activity loss from repeated freeze-thaw cycles.
Is Vilon suitable for human consumption or therapeutic use?
No. Vilon sold by PX1 Research is strictly intended for laboratory research and in vitro experimentation. It is not approved for clinical, medical, therapeutic, or human use.
What solvents are recommended for reconstituting Vilon in lab assays?
Due to the polar, hydrophilic nature of Lys-Glu, Vilon dissolves rapidly in sterile laboratory-grade water or phosphate-buffered saline (PBS, pH 7.4).
Where are PX1 Research compounds manufactured and shipped from?
All PX1 Research compounds are manufactured in US-based, GMP-compliant facilities and shipped directly from fulfillment centers in California and Arizona.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.